## Jeanette M Jerrell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3785727/publications.pdf

Version: 2024-02-01

304743 345221 1,500 61 22 36 citations h-index g-index papers 61 61 61 2168 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents. JAMA Pediatrics, 2008, 162, 929.	3.0	158
2	The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project. Comprehensive Psychiatry, 2015, 56, 279-282.	3.1	123
3	A Cohort Study of the Prevalence and Impact of Comorbid Medical Conditions in Pediatric Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 1518-1525.	2.2	94
4	Adverse events in children and adolescents treated with antipsychotic medications. Human Psychopharmacology, 2008, 23, 283-290.	1.5	66
5	Advancing biomarker research: utilizing †Big Data' approaches for the characterization and prevention of bipolar disorder. Bipolar Disorders, 2014, 16, 531-547.	1.9	57
6	Polypharmacy in Children and Adolescents Treated for Major Depressive Disorder. Journal of Clinical Psychiatry, 2009, 70, 240-246.	2.2	51
7	Psychometrics of the Recovery Process Inventory. Journal of Behavioral Health Services and Research, 2006, 33, 464-473.	1.4	46
8	Cost-Effectiveness of Risperidone, Olanzapine, and Conventional Antipsychotic Medications. Schizophrenia Bulletin, 2002, 28, 589-605.	4.3	41
9	Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease. Annals of Hematology, 2011, 90, 145-150.	1.8	41
10	Cost-effectiveness of substance disorder interventions for people with severe mental illness. Journal of Mental Health Administration, 1994, 21, 283-297.	1.1	40
11	Issues and outcomes in integrated treatment programs for dual disorders. Journal of Behavioral Health Services and Research, 2000, 27, 303-313.	1.4	40
12	Population-Based Treated Prevalence of Congenital Heart Disease in a Pediatric Cohort. Pediatric Cardiology, 2013, 34, 606-611.	1.3	39
13	Prevalence and Treatment of Depression in Children and Adolescents With Sickle Cell Disease. primary care companion for CNS disorders, The, 2011, 13, .	0.6	38
14	Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. American Journal of Hematology, 2010, 85, 795-797.	4.1	35
15	Psychometrics of the MHSIP Adult Consumer Survey. Journal of Behavioral Health Services and Research, 2006, 33, 483-488.	1.4	32
16	Neuroendocrineâ€Related Adverse Events Associated with Antidepressant Treatment in Children and Adolescents. CNS Neuroscience and Therapeutics, 2010, 16, 83-90.	3.9	32
17	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectrums, 2016, 21, 362-366.	1.2	31
18	Neurological Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents. Journal of Child Neurology, 2008, 23, 1392-1399.	1.4	28

#	Article	IF	CITATIONS
19	Factors Associated With the Occurrence and Treatment of Supraventricular Tachycardia in a Pediatric Congenital Heart Disease Cohort. Pediatric Cardiology, 2014, 35, 368-373.	1.3	27
20	Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder. European Child and Adolescent Psychiatry, 2015, 24, 65-73.	4.7	25
21	Incidence and Costs of Cardiometabolic Conditions in Patients with Schizophrenia Treated with Antipsychotic Medications. Clinical Schizophrenia and Related Psychoses, 2010, 4, 161-168.	1.4	25
22	Correlates of Incident Bipolar Disorder in Children and Adolescents Diagnosed With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2014, 75, e1278-e1283.	2.2	23
23	Pain management in children and adolescents with sickle cell disease. American Journal of Hematology, 2011, 86, 82-84.	4.1	22
24	Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Pediatric Blood and Cancer, 2011, 56, 90-94.	1.5	21
25	Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescentâ€onset bipolar disorder. Human Psychopharmacology, 2011, 26, 451-459.	1.5	21
26	Community-based care for youths with early and very-early onset bipolar I disorder. Bipolar Disorders, 2004, 6, 299-304.	1.9	20
27	Hyperprolactinemia-Related Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents. Journal of Adolescent Health, 2009, 45, 70-76.	2.5	20
28	Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. Obesity Research and Clinical Practice, 2016, 10, 531-543.	1.8	20
29	Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia. Schizophrenia Research and Treatment, 2013, 2013, 1-9.	1.5	19
30	Gender Differences in the Assessment of Specialized Treatments for Substance Abuse among People with Severe Mental Illness. Journal of Psychoactive Drugs, 1995, 27, 347-355.	1.7	14
31	Use and Costs of Public-Sector Behavioral Health Services for African-American and White Women. Psychiatric Services, 2002, 53, 195-200.	2.0	14
32	Behavior and symptom identification scale 32. Journal of Behavioral Health Services and Research, 2005, 32, 341-346.	1.4	14
33	Prevalence, Treatment, and Outcomes of Renal Conditions in Pediatric Sickle Cell Disease. Southern Medical Journal, 2011, 104, 752-756.	0.7	13
34	Prevalence and Management of Patent Ductus Arteriosus in a Pediatric Medicaid Cohort. Clinical Cardiology, 2013, 36, 502-506.	1.8	13
35	Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents. Human Psychopharmacology, 2017, 32, e2589.	1.5	13
36	A comparison of the PANSS Pentagonal and Van Der Gaag 5-factor models for assessing change over time. Psychiatry Research, 2013, 207, 134-139.	3.3	12

#	Article	IF	CITATIONS
37	Incidence of primary hypertension in a population–based cohort of HIV–infected compared with non–HIV–infected persons and the effect of combined antiretroviral therapy. Journal of the American Society of Hypertension, 2015, 9, 351-357.	2.3	12
38	Risk Factors for Heart Failure and Its Costs Among Children with Complex Congenital Heart Disease in a Medicaid Cohort. Pediatric Cardiology, 2017, 38, 1672-1679.	1.3	11
39	A comparison of the phenomenology and treatment of youths and adults with bipolar I disorder in a state mental health system. Journal of Affective Disorders, 2004, 80, 29-35.	4.1	10
40	Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Human Psychopharmacology, 2007, 22, 361-364.	1.5	10
41	Cardiovascular and Neurological Adverse Events Associated With Antidepressant Treatment in Children and Adolescents. Journal of Child Neurology, 2009, 24, 297-304.	1.4	10
42	Adverse Events Associated With Psychotropic Treatment in African American Children and Adolescents. Journal of the National Medical Association, 2010, 102, 375-383.	0.8	10
43	Neurological and Cardiovascular Adverse Events Associated with Antimanic Treatment in Children and Adolescents. CNS Neuroscience and Therapeutics, 2010, 16, 25-31.	3.9	10
44	The Risk of Developing Type 2 Diabetes Mellitus Associated With Psychotropic Drug Use in Children and Adolescents. primary care companion for CNS disorders, The, 2012, 14, .	0.6	10
45	Factors Differentiating Childhood-Onset and Adolescent-Onset Schizophrenia. primary care companion for CNS disorders, The, 2016, 18, .	0.6	10
46	Population-based treated prevalence, risk factors, and outcomes of bicuspid aortic valve in a pediatric Medicaid cohort. Annals of Pediatric Cardiology, 2018, 11, 119.	0.5	10
47	Pharmacotherapy in the communityâ <b>€b</b> ased treatment of children with bipolar I disorder. Human Psychopharmacology, 2008, 23, 53-59.	1.5	9
48	Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications. Human Psychopharmacology, 2008, 23, 595-604.	1.5	9
49	Economic Grand Rounds: Economic Costs of Failure to Monitor Adverse Effects of Second-Generation Antipsychotics: An Underestimated Factor. Psychiatric Services, 2012, 63, 202-204.	2.0	9
50	Prevalence of Treatment, Risk Factors, and Management of Atrial Septal Defects in a Pediatric Medicaid Cohort. Pediatric Cardiology, 2013, 34, 1723-1728.	1.3	9
51	Factors Associated With Musculoskeletal Injuries in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. primary care companion for CNS disorders, The, 2016, 18, .	0.6	8
52	Health-Care Costs of Pediatric Clients Developing Adverse Events during Treatment with Antipsychotics. Value in Health, 2009, 12, 716-722.	0.3	5
53	Epidemiology of Pediatric Hypertrophic Cardiomyopathy in a 10-Year Medicaid Cohort. Pediatric Cardiology, 2021, 42, 210-214.	1.3	5
54	Outcomes for Youths with Early- and Very-Early-Onset Bipolar I Disorder. Journal of Behavioral Health Services and Research, 2008, 35, 52-59.	1.4	4

#	Article	IF	CITATIONS
55	Long-Term Neurodevelopmental Outcomes in Children and Adolescents With Congenital Heart Disease. primary care companion for CNS disorders, The, 2015, 17, .	0.6	4
56	Letters to the Editor. Clinical Schizophrenia and Related Psychoses, 2011, 5, 54-54.	1.4	2
57	Metabolic, Digestive, and Reproductive Adverse Events Associated With Antimanic Treatment in Children and Adolescents. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, .	0.6	2
58	Changes in cognitive function associated with syndrome changes on two fiveâ€factor models of the Positive and Negative Syndrome Scale. Human Psychopharmacology, 2012, 27, 566-576.	1.5	1
59	Factors associated with musculoskeletal injuries in children and adolescents with sickle cell disease. American Journal of Hematology, 2016, 91, E314-6.	4.1	1
60	Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia. Human Psychopharmacology, 2017, 32, e2585.	1.5	1
61	Letter to editor: Incident depression increases medical utilization in Medicaid patients with hypertension. Expert Review of Cardiovascular Therapy, 2015, 13, 15-16.	1.5	0